Skip to main content

Table 1 Baseline demographic, laboratory and radiological characteristics of the study patients and controls

From: Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience

Variable SRB+CTB SRB Supportive p
Age (years) 49.5 ± 5.2 47.2 ± 4.6 46.6 ± 4.3 0.2
BMI k/m2 27.7 ± 0.9 26.8 ± 0.5 27 ± 1.3 0.03
AST IU/l 97.6 ± 26.5 68 ± 15 89.5 ± 28.4 0.005
ALT IU/l 65 ± 12.2 85 ± 17 73.8 ± 11.5 0.001
Albumin gm/dl 3.37 ± 0.32 3.6 ± 0.3 3.4 ± 0.3 0.09
T.Bilirubin mg/dl 2.03 ± 0.3 1.94 ± 0.9 2.2 ± 0.4 0.48
WBC cell/µl 3.7 ± 0.3 4.3 ± 0.4 3.6 ± 0.5 0.000
HB gm/dl 11.2 ± 0.8 11.6 ± 0.6 10.9 ± 0.5 0.02
Platelets cell/µl 91.3 ± 8.3 100 ± 7 94.2 ± 10.2 0.03
INR 1.35 ± 0.08 1.32 ± 0.3 1.4 ± 0.1 0.5
Creatinine mg/dl 1.2 ± 0.5 0.9 ± 0.4 1.1 ± 0.3 0.14
CTP 6.3 ± 0.3 6.7 ± 0.7 6.5 ± 0.2 0.07
MELD 13.7 ± 1.4 14.2 ± 1.6 14 ± 1.2 0.6
AFP ng/dl (mean ± SE) 6211 ± 929 3154 ± 345 2710 ± 581 0.000
No of focal lesions 2.5 ± 1.1 2.4 ± 0.3 2.4 ± 0.9 0.9
Size (cm) 10.5 ± 4.1 11.2 ± 6.3 8.7 ± 2.4 0.3
PVT (n) 11(73.3 %) 12 (75 %) 9 (60 %) 0. 8
Survival (months) 12.9 ± 2.1 7.9 ± 0.9 4.5 ± 1.3 0.000
  1. Italic values indicate significant differences when p < 0.05
  2. SRB sorafenib, CTB capcitabine, BMI body mass index, CTP child turcott pugh, MELD model for end stage liver disease, AFP alfafetoprotein